Conversely, the inhibition of ER signaling, either alone or in combination with HER2-targeted therapies, can enhance the efficacy of HER2-targeted treatments by sensitizing HER2-positive breast cancer cells to therapy [22]. This evidence concerns the gene ESR1 and breast carcinoma.